Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project

References

• Hallert E, Björk M, Dahlström O, Skogh T, Thyberg I. Disease activity and disability in women and men with early rheumatoid arthritis (RA): an 8-year followup of a Swedish early RA project. Arthritis Care Res 2012;64:1101–7.
   PubMed Web of Science ®Google Scholar
• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(Suppl 1):1–12.
   PubMed Web of Science ®Google Scholar
• Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA Project). Rheumatology 2004;43:1374–82.
   PubMed Web of Science ®Google Scholar
• Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S71–4.
   PubMed Web of Science ®Google Scholar
• Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:S118–23.
   PubMed Web of Science ®Google Scholar
• Burmeister GD. RA in 2011: advances in diagnosis, treatment and definition of remission. Nature Rev Rheumatol 2012;8:65–6.
   Web of Science ®Google Scholar
• Breedvelt FC, Combe B. Understanding emerging treatment paradigms in rheumatoid artrhritis. Arthritis Res Ther 2011;13(Suppl 1):S3.
   PubMedGoogle Scholar
• Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011;13(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis 2010;69:352–7.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010;12:R35.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712–20.
   PubMed Web of Science ®Google Scholar
• Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology 2006 45:325–31.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• Svärd A, Kastbom A, Reckner-Olsson A, Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol 2011;38:1265–72.
   PubMed Web of Science ®Google Scholar
• Ekdahl C, Eberhardt KB, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1988;17:263–71.
   PubMed Web of Science ®Google Scholar
• Serden L, Lindquist R, Rosen M. Have DRG-based prospective payment systems influenced the number of secondary diagnoses in health care administrative data? Health Policy 2003;65:101–17.
   PubMed Web of Science ®Google Scholar
• Petersson IF. Team care. Traditions and new trends. J Rheumatol 2006;33:1895–6.
   PubMed Web of Science ®Google Scholar
• Zirkzee EJ, Sneep AC, de Buck PD, Allaart CF, Peeters AJ, Ronday HK, Sick leave and work disability in patients with early arthritis. Clin Rheumatol 2008;27:11–19.
   PubMedGoogle Scholar
• Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716–22.
   PubMed Web of Science ®Google Scholar
• Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467–74.
   PubMed Web of Science ®Google Scholar
• Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12:R42.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2211–17.
   PubMed Web of Science ®Google Scholar
• Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008;59:1082–9.
   PubMed Web of Science ®Google Scholar
• Olofsson T, Englund M, Saxne T, Jöud A, Jacobsson LT, Geborek P, Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists a population-based controlled cohort study. Ann Rheum Dis 2010;69:2131–6.
   PubMed Web of Science ®Google Scholar
• Neovius M, Simard JF, Askling J; ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis 2011;70:1010–15.
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Ruof J, Huelsemann JL, Mittendorf T, Handelmann S, Mau W, Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005;53:234–40.
   PubMed Web of Science ®Google Scholar
• Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, Biological vs conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. JAMA Intern Med. Published online: 1 July 2013. doi:10.1001/jamainternmed.2013.7801.
   Google Scholar
• Hallert E, Husberg M, Bernfort L. The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990-2010: before and after introduction of biologic agents. Rheumatology 2012;51:338–46.
   PubMed Web of Science ®Google Scholar
• Chung CP, Sokka T, Arbogast PG, Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006;65:1653–7.
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Ruof J, Schöffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528–34.
   PubMed Web of Science ®Google Scholar
• Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10:460–6.
   PubMed Web of Science ®Google Scholar
• Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012;6:989–92.
   Google Scholar
• Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30:S72–84.
   PubMed Web of Science ®Google Scholar